Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.52 |
| ▸ | MC3R | P41968 | 7/20 | 0.46 |
| ▸ | MC5R | P33032 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13493164 | 1.00 | MC4R (0.52) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL1919957 | 0.89 | MC4R (0.49) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL1919904 | 0.88 | MC4R (0.45) | MC4RMC3RMC5RKCNH2 | |
| SCHEMBL1919958 | 0.80 | MC4R (0.40) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL13493166 | 0.80 | MC4R (0.44) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL12536957 | 0.80 | MC4R (0.44) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL12536955 | 0.79 | DPP4 (0.51) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL13493172 | 0.79 | DPP4 (0.51) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL15016124 | 0.79 | DPP4 (0.51) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL1945989 | 0.79 | MC4R (0.43) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592403-B2 | Diazepine and diazocane compounds as MC4 agonists | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2326638-B9 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-11-13 | — | — | EP | disclosed |
| EP-2326638-B1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| WO-2010015972-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | MC4R 1/4885MC3R 16/4885MC5R 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.